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to blood pressure and risk of cardiovascular disease in
German adults’
†, by B. Buijsse et al., on page 1616
Dietisalifestylefactorthatplaysamajorroleintheprimaryandsec-
ondary prevention of numerous chronic diseases, including certain
cancers, cardiovascular disease, and diabetes.
1 Current dietary rec-
ommendations endorse the consumption of a diet rich in fruit and
vegetables,asitisnowrecognizedthatthesearehealthyformultiple
reasons.
2Inadditiontobeinglowincaloriesandfat,andhighinﬁbre,
plant-based foods can also contain a number of potentially health-
promotingbioactivephytochemicals.Recently,ﬂavanols,asubgroup
of plant-derived compounds called ﬂavonoids, have gained increas-
ing attention as epidemiological investigations have revealed an
inverse correlation between the dietary intake of ﬂavanol-
containing foods and coronary artery disease (CAD) mortality,
with a reduction of mortality risk of up to 51% (Figure 1).
3 In the
context of human nutrition, major ﬂavanol sources in the western
diet include tea, grapes and wine, cocoa products including choco-
late, as well as various fruits, especially apples, and certain berries.
While subject to agricultural practices and food processing, particu-
larly highﬂavanollevels can be presentin cocoa.
4 Severalcontrolled
human dietary intervention studies utilizing ﬂavanol-containing
foods in concert with nutrient-matched low-ﬂavanol controls
have demonstrated a causal relationship between ﬂavanol intake
and the modulation of (patho)physiological functions involved in
the development and progression of vascular disease. In this
context, the attenuation of endothelial dysfunction, decreases in
blood pressure, reductions in platelet aggregation, and improve-
ments in insulin sensitivity have been observed following clinical
dietary interventions with ﬂavanol-containing foods and beverages.
5
Buijsse and colleagues have presented an epidemiological study
that demonstrates an inverse relationship between chocolate
consumption (at the time of enrolment in the study) and
cardiovascular disease risk (myocardial infarction and stroke over
the following 8 years).
6 Buijsse et al. studied a large cohort (n ¼
19 357) of middle-aged German participants of both sexes,
without cardiovascular disease at inclusion, and observed that in
the quartile characterized by the lowest chocolate consumption
(1.7 g/day) 106 myocardial infarctions and strokes occurred,
whereas only 61 events occurred (combined relative risk of
0.61) in the quartile with the highest chocolate consumption
(7.5 g/day). In the latter group, both systolic and diastolic blood
pressure were found to be 1 mmHg lower as compared with the
referent low chocolate consumption quartile. Baseline blood
pressure explained 10–12% of the risk reduction. Counterintui-
tively to the accepted view that high vegetable intake is associated
with cardiovascular beneﬁts, the subgroup with the lowest risk was
also the group with the lowest vegetable intake while also having
the highest chocolate intake. Generally, the results of the study
by Buijsse et al. corroborate previous ﬁndings emanating from
other western countries that show an association between
higher intake of ﬂavanol-rich foods, including chocolate, and
lower incidence of cardiovascular events in elderly Dutch men
(Zutphen Elderly Study)
7 and post-menopausal American women
(Iowa Women’s Health Study).
8 The study by Buijsse et al.
extends these ﬁndings to German middle-aged subjects of both
sexes, and statistically links a small proportion of the cardiovascular
beneﬁt (11%) to higher chocolate consumption and lower blood
pressure.
While these ﬁndings certainly spark interest, it is inherent to epi-
demiological investigations that they cannot provide direct proof
for the existence of a cause and effect relationship. However,
are there conclusive prospective intervention studies that
support a causal relationship between chocolate intake and
blood pressure lowering? Ideally, such studies should be performed
over a meaningful period of time, be adequately powered, and they
need to be well controlled in order to yield sufﬁciently conclusive
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doi:10.1093/eurheartj/ehq114results. As cocoa and therefore chocolate contains various bioac-
tives, i.e. ﬂavanols, theobromine, caffeine, and others, the content
of these bioactive compounds needs to be considered in the design
of a proper control product. In order to reduce bias, the macro-
and micronutrient composition as well as ﬂavour and appearance
need to be taken into account. Although no published study cur-
rently exists that meets all of the above criteria, in the context
of a dietary intervention based on chocolate, the study by
Taubert et al.
9 perhaps comes closest and has gained much atten-
tion. In the latter study, participants with untreated essential hyper-
tension received 6.3 g of dark chocolate per day over 18 weeks,
and a signiﬁcant drop in systolic and diastolic blood pressure was
observed. One major limitation of this data set is the fact that
white chocolate was used as a control food product, which
makes masking of patients and observers impossible, thus increas-
ing the risk of bias. Furthermore, the different compositions of
white and dark chocolate makes it difﬁcult to identify bioactive
compounds, such as ﬂavanols, in the context of blood pressure
lowering. Whereas white chocolate lacks ﬂavanols, it also lacks
methylxanthines and has a different fat composition. Overall, it
might be argued that we do not have conclusive data from sufﬁ-
ciently controlled interventional trials to support the notion that
chocolate consumption can lower blood pressure.
As outlined above, epidemiological studies have statistically
linked the cardiovascular protective effects of certain foods includ-
ing tea, various fruits, and cocoa to their high ﬂavanol content. As
cocoa is the main ﬂavanol-delivering ingredient in chocolate, the
ﬁndings from cocoa intervention studies may be used, with
certain limitations kept in mind, to construct a feasible physiologi-
cal link between chocolate consumption and cardiovascular risk
reduction. Indeed, well-controlled small-scale human intervention
studies have established a causal relationship between the intake
of ﬂavanols and the increase of endothelium-dependent vasodila-
tion. In these intervention studies, ﬂavanol-rich cocoa products
were tested against micro- and macronutrient-matched controls
in randomized trials ensuring proper blinding. It was shown that
high ﬂavanol interventions can induce an acute and sustained
increase or restoration, respectively, of endothelium-dependent
vasodilation in healthy subjects with cardiovascular risk factors
(smoking, diabetes mellitus, hypertension, hypercholesterolaemia),
heart transplant recipients, or patients with manifest coronary
artery disease. In most studies, endothelium-dependent vasodila-
tion was measured as ﬂow-mediated vasodilation (FMD) which
represents a prospectively validated surrogate endpoint predicting
cardiovascular prognosis. These effects were shown to be dose
dependent, inhibited by nitric oxide synthase blockers, and were
paralleled by an increase in nitric oxide stores in blood, suggesting
a mechanistic role for this pathway in this context. Importantly, a
causality chain between ﬂavanols in food and nitric oxide-
dependent vascular function was ﬁrst experimentally closed by
Schroeter et al. and then further substantiated by another indepen-
dent group who showed that intake of chemically pure ﬂavanols
[(–)-epicatechin] mimics the vascular effects observed after inges-
tion of ﬂavanol-rich cocoa.
10,11
In the context of the study by Buijsse et al.
6, one of the major
shortcomings is that chocolate consumption was only estimated
as one item on the food-frequency questionnaire, making a more
qualiﬁed evaluation of the associated intake of potential bioactives
including favanols impossible. This is an important limitation as not
every chocolate, or cocoa for that matter, is created equally. The
Figure 1 Schematic of ﬂavanol effects on the cardiovascular system.
Editorial 1555cocoa content varies greatly between chocolates, and the ﬂavanol
content and proﬁle differ greatly between cocoas. Yet another
layer of complexity should be considered carefully, namely that ﬂa-
vanols exist in distinct stereochemical conﬁgurations. This topic
has not yet been comprehensively explored, but as stereo-
chemistry is a known factor inﬂuencing bioactivity, and as food pro-
cessing affects the stereochemical conﬁguration of favanols, this
topic should be considered in the context of both epidemiological
studies and dietary interventions.
While chocolate represents a wonderfully delicious treat that
can doubtlessly be a healthy part of a balanced diet, cardiologists
need to consider how best to communicate such ﬁndings and
ask the important question as to whether or not they should
directly or indirectly recommend to their patients an increased
consumption of chocolate, a food relatively high in saturated fat,
sugar, and calories.
Funding
M.K. is supported by the Deutsche Forschungsgemeinschaft (Ke405/
5-1). C.H. receives research funding from the Forschungskommission
of the Heinrich-Heine University, Du ¨sseldorf. C.H. and M.K. have
received unrestricted research funding from Mars Inc. and are senior
investigators in the FLAVIOLA research consortium of the European
Union (FP7-KBBE-2008-2B). Funding to pay the Open Access
publication charges for this article was provided by the Division of
Cardiology, Vascular Medicine, and Pulmonology, Heinrich-Heine
University Du ¨sseldorf.
Conﬂict of interest: none declared.
References
1. Eyre H, Kahn R, Robertson RM, Clark NG, Doyle C, Hong Y, Gansler T, Glynn T,
Smith RA, Taubert K, Thun MJ. Preventing cancer, cardiovascular disease, and dia-
betes: a common agenda for the American Cancer Society, the American Dia-
betes Association, and the American Heart Association. Circulation 2004;109:
3244–3255.
2. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA,
Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M,
Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Diet and lifestyle rec-
ommendations revision 2006: a scientiﬁc statement from the American Heart
Association Nutrition Committee. Circulation 2006;114:82–96.
3. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J
Clin Nutr 2005;81:317S–325S.
4. Williamson G, Manach C. Bioavailability and bioefﬁcacy of polyphenols in humans.
II. Review of 93 intervention studies. Am J Clin Nutr 2005;81:243S–255S.
5. Desch S, Schmidt J, Kobler D, Sonnabend M, Eitel I, Sareban M, Rahimi K,
Schuler G, Thiele H. Effect of cocoa products on blood pressure: systematic
review and meta-analysis. Am J Hypertens 2010;23:97–103.
6. Buijsse B, Weikert C, Drogan D, Bergmann M, Boeing H. Chocolate consumption
in relation to blood pressure and risk of cardiovascular disease in German adults.
Eur Heart J; doi:10.1093/eurheartj/ehq068. Published online ahead of print 30
March 2010.
7. Buijsse B, Feskens EJ, Kok FJ, Kromhout D. Cocoa intake, blood pressure, and car-
diovascular mortality: the Zutphen Elderly Study. Arch Intern Med 2006;166:
411–417.
8. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, Jacobs DR
Jr. Flavonoid intake and cardiovascular disease mortality: a prospective study in
postmenopausal women. Am J Clin Nutr 2007;85:895–909.
9. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E. Effects of low habitual
cocoa intake on blood pressure and bioactive nitric oxide: a randomized con-
trolled trial. JAMA 2007;298:49–60.
10. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H,
Kwik-Uribe C, Schmitz HH, Kelm M. (–)-Epicatechin mediates beneﬁcial effects
of ﬂavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci USA
2006;103:1024–1029.
11. Loke WM, Hodgson JM, Proudfoot JM, McKinley AJ, Puddey IB, Croft KD. Pure
dietary ﬂavonoids quercetin and (–)-epicatechin augment nitric oxide products
and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr 2008;88:
1018–1025.
Editorial 1556